302440:KRXSK bioscience Co.,Ltd. Analysis

SK bioscience is trading at KRW 40,550, just above its 20‑day SMA (KRW 40,487) but comfortably below the 50‑day (KRW 41,914) and 200‑day (KRW 47,427) averages, confirming a bearish market bias. Technical signals reinforce this view: the MACD histogram is negative, RSI sits at 49 (neutral‑to‑weak), and volume has been decreasing, while 30‑day volatility spikes at 44.7%, indicating unstable price action. Fundamentally, the company posts a 9% revenue rise but suffers from a 26% operating loss, a negative gross margin of 9.6%, and a distressing debt‑to‑equity ratio of 26.6, with cash flow deeply negative. Analysts rate the stock “underperform,” set a median target of KRW 31,000 (≈‑19% downside), and the market sentiment index reads “Extreme Greed,” suggesting price may be driven more by speculation than substance.
Given the weak earnings profile, high leverage, and lack of dividend, the stock appears overvalued relative to its earnings‑free cash flow and sector peers. While the pipeline of vaccines offers a distant upside, the immediate outlook is constrained by regulatory hurdles, high debt servicing needs, and a deteriorating technical environment.